



Pharma **POOL**

Lamberto **ANDREOTTI**

Bristol-Myers Squibb Promotes President, Worldwide Pharmaceuticals



Bristol-Myers Squibb has promoted Lamberto Andreotti to executive VP and president of Worldwide Pharmaceuticals. Based in New York, Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company. Mr. Andreotti oversees the company's consolidated global pharmaceutical operations, following the reorganization of its operating units.

Most recently, Mr. Andreotti served as senior VP and president, international, with responsibility for the company's pharmaceutical operations in Europe, the Middle East, Africa, Japan, and Asia-Pacific.

Dr. Henry J. **FUCHS**

Onyx Names Executive VP and Chief Medical Officer

Onyx Pharmaceuticals has appointed Henry (Hank) J. Fuchs, M.D., as executive VP and chief medical officer. Onyx Pharmaceuticals, Emeryville, Calif., develops novel therapies that target the molecular basis of cancer. In this newly created position, Dr. Fuchs, 48, is responsible for research and development, including clinical development, medical affairs, regulatory affairs, and compliance functions.

Most recently, he was CEO of IntraBiotics, and he continues to serve on the company's board. He earned a M.D. from George Washington University and a B.A. in biochemical sciences from Harvard College.

Dr. John C. **LECHLEITER**

Lilly Promotes President and Chief Operating Officer



Eli Lilly has appointed John C. Lechleiter, Ph.D., to president and chief operating officer. He also has joined the company's board of directors. Based in Indianapolis, Lilly is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products.

Dr. Lechleiter has been with Lilly since 1979 and most recently served as executive VP, responsible for pharmaceutical and U.S. operations. He earned his Ph.D. in organic chemistry from Harvard University.

Tony **ZOOK**

AstraZeneca Appoints U.S. Chief



AstraZeneca, an international healthcare business based in London that is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals, has appointed Tony Zook as executive VP, North America, and president and CEO of AstraZeneca U.S., effective January 1, 2006.

Mr. Zook has more than 20 years of phar-

maceutical industry experience and is currently the company's senior VP, U.S. commercial operations. Previously, he was VP of sales for AstraZeneca. He holds a bachelor's degree in biology from Frostburg University.

He will succeed David R. Brennan, who has been named CEO of AstraZeneca PLC. Mr. Brennan assumes his role following the retirement of Sir Tom McKillop, who has led the company since 1999.

Biotech **POOL**

Dr. Cindy **JACOBS**

Dr. Monica **KRIEGER**

OncoGenex Hires Senior Executives

OncoGenex Technologies, a clinical-stage biotechnology company in Vancouver, British Columbia, has appointed Cindy Jacobs, Ph.D., M.D., to the position of executive VP and chief medical officer. She oversees the advancement of OncoGenex's pipeline of preclinical and clinical oncology product candidates.

Dr. Jacobs brings more than 20 years of biotechnology industry experience and was most recently senior VP of clinical development and chief medical officer at Corixa. She received her Ph.D. from Washington State University and her M.D. from the University of Washington Medical School.

Additionally, OncoGenex has appointed Monica Krieger, Ph.D., to VP of regulatory affairs. She manages the company's relationships with international regulatory agencies.

Dr. Krieger has 23 years of regulatory and clinical affairs experience. She most recently was VP of regulatory affairs at Corixa. Dr. Krieger received her Ph.D. from Rutgers University and her MBA from the Darden School at the University of Virginia.

Kevin **MCNELLY**

James **MILLER**

Kevin **ROONEY**

Dr. Mauricio

VARGAS-CORTES

MedImmune Appoints Four VPs

MedImmune, Gaithersburg, Md., a biotechnology company focused on the areas of infectious diseases, cancer, and inflammato-

ry diseases, has appointed four VPs to its executive leadership team.



Kevin McNelly has joined the company as VP, supply chain operations, responsible for the department's overall strategic direction, emphasizing continued operational integration and development of scalable, customer-focused solutions.

Most recently, Mr. McNelly was VP, solution management, for Manugistics. He holds a bachelor's degree in mechanical engineering from the Rose-Hulman Institute of Technology.



MedImmune also has hired James Miller as VP, international, business analysis, and new products. He is responsible for setting the strategic direction for MedImmune in international markets, supporting the commercialization efforts of current and future products through business analyses, and leading the commercial development of new products from research to launch.

He has joined MedImmune from KTM Consulting, where he was executive director, international management and strategic planning. A certified public accountant, Mr. Miller holds a bachelor's degree in accounting from Hillsdale College.



MedImmune has promoted Kevin Rooney to VP, oncology sales and marketing. In this position, he provides strategic oversight of the sales and marketing organization for the company's marketed oncology product, Ethyol. He previously served as MedImmune's senior director of marketing for Synagis.

Previously, Mr. Rooney was with Bristol-Myers Squibb, where he held a number of positions with increasing responsibility in both sales and marketing management. He holds a master's degree in management from Northwestern University and a bachelor's degree from the University of Virginia.



Mauricio Vargas-Cortes, Ph.D., has joined MedImmune as VP, project management. He is responsible for the company's project planning and alliance management efforts.

Previously, Dr. Vargas-Cortes held a number of project management and clinical development positions with Eli Lilly. He holds B.S. degrees in microbiology

and biology from the University of Los Andes in Bogota, Colombia, and a Ph.D. in immunology from the University of Stockholm, Sweden.

Biopharmaceutical POOL

Dr. Sarbani BHADURI

Acologix Names VP, Medical Affairs

Acologix, Hayward, Calif., a privately held biopharmaceutical company targeting bone and kidney diseases, has appointed Sarbani Bhaduri, M.D., as VP of medical affairs.

A board-certified nephrologist with experience in early-to-late stage clinical development, Dr. Bhaduri most recently was the nephrology franchise medical director for Ortho Biotech. She received her B.S. from the University of Texas at El Paso and her M.D. at Texas Tech University, School of Medicine.

Dr. Peter CALCOTT

PDL Names VP, Quality and Compliance


Peter Calcott, Ph.D., has been named VP of quality and compliance at Protein Design Labs (PDL), a Fremont, Calif.-based biopharmaceutical company focused on novel therapies for inflammation and autoimmune diseases, acute cardiac conditions, and cancer.

In the newly created position, Dr. Calcott has responsibility for overseeing quality and compliance operations across all four of the company's sites in California, Minnesota, New Jersey, and Paris.

He most recently served as corporate VP of quality at Chiron. He holds a bachelor of science degree from the University of East Anglia and a doctorate from the University of Sussex.

Dr. Gordana KOSUTIC

Tranzyme Names VP, Clinical and Regulatory Affairs



Tranzyme Pharma, Durham, N.C., a leading biopharmaceutical company developing treatments for gastrointestinal diseases, has appointed Gordana Kosutic, M.D., as VP of clinical and regulatory affairs.

Dr. Kosutic brings 25 years of experience in all aspects of clinical research. She previous-

ly held senior executive positions at Fulcrum Pharma Developments, Nobex, ClinTrials Research (now part of Charles River Laboratories), and ICN Pharmaceuticals.

Dr. Robert W. LEE

Novavax Appoints VP, Pharmaceutical Development

Novavax, a specialty biopharmaceutical company based in Malvern, Pa., has appointed Robert W. Lee, Ph.D., as VP of pharmaceutical development.

Dr. Lee, 45, has more than 15 years experience in pharmaceutical research and development, most recently as VP of product development for Lyotropic Therapeutics. He also serves as chief scientific advisor for NanoScan Imaging.

He earned a Ph.D. in physical bio-organic chemistry from the University of California, Santa Barbara. He also holds B.Sc. degrees in chemistry and biology from the University of Washington.

Dr. Martin A.

MATTINGLY

Ambrx Appoints President and CEO

Martin A. Mattingly, Pharm.D., has been named president, CEO, and director of Ambrx, a San Diego-based biopharmaceutical company focused on protein-based medicines.

Most recently, he was executive VP and chief operating officer at CancerVax. He previously has held senior leadership positions at Agouron Pharmaceuticals and Pfizer. He holds a doctorate in pharmacy from the University of Kentucky.

Richard J. MORAN

Genta Appoints Senior VP, Chief Financial Officer



Genta has appointed Richard J. Moran as senior VP and chief financial officer. He also serves as corporate secretary and will have reporting responsibility for finance, manufacturing operations, and information technology. Genta, Berkeley Heights, N.J., is a biopharmaceutical company focused on delivering innovative cancer treatment products.

A certified public accountant, Mr. Moran has extensive and diversified finance experience from a long career with Johnson & Johnson and several of its operating companies.

Most recently, he was director of special projects at J&J's corporate headquarters. Previously, he spent seven years as chief financial officer, VP of finance, and member of the U.S. board for Ortho Biotech.

Mr. Moran succeeds William Keane, who resigned the position but continues to serve Genta as a consultant.

Dr. Patricia **WALICKE**

Avidia Appoints VP

Patricia Walicke, M.D., Ph.D., has been named VP of clinical and regulatory affairs at Avidia, Mountain View, Calif., a biopharmaceutical company focused on the development and commercialization of a new class of protein therapeutics.

Dr. Walicke brings almost 10 years of experience in the clinical and regulatory development of protein drugs. She previously was the VP of clinical development at Rinat Neuroscience. She holds M.D. and Ph.D. degrees from Harvard University.

Specialty **POOL**

Michael **ASTRUE**

Epix Pharmaceuticals Appoints Interim CEO



Epix Pharmaceuticals, Cambridge, Mass., a developer of innovative pharmaceuticals for magnetic resonance imaging (MRI), has appointed Michael Astrue as interim CEO. In this role, he helps the company execute its business plan, define and pursue opportunities for growth, and search for a permanent CEO.

Mr. Astrue previously served as president and CEO of Transkaryotic Therapies. He holds a B.A. from Yale University and a J.D. from Harvard Law School. He also serves on the boards of three publicly traded biotechnology companies: Tercica, Curagen, and ArQule.

He has succeeded Michael Webb, who remains a consultant to the company.

Christopher **DOWD**

Esprit Pharma Names Senior VP, Sales

Esprit Pharma, East Brunswick, N.J., a



specialty pharmaceutical company focused on the urology therapeutic area, has appointed Christopher Dowd as senior VP of sales.

Previously, Mr. Dowd spent 19 years at Pfizer, where he was inducted into the company's Sales Hall of Fame. Most recently, he was VP of specialty sales in Pfizer's world headquarters. He is a graduate of Farleigh Dickinson University.

Thomas P. **JENNINGS**

PediaMed Appoints Chief Administrative Officer

PediaMed – The Pediatrics Company, Florence, Ky., a company specializing in the health and well-being of children, has appointed Thomas P. Jennings as VP, chief administrative officer. He is responsible for the legal affairs function, managing contract review with vendors related to products, manufacturing partners, and agencies; developing and executing corporate public relations plans, discharging all duties associated with the role of company secretary, and actively participating in business and corporate development.

Mr. Jennings brings to PediaMed an extensive background in specialty pharmaceuticals. He most recently served as president of Union Springs, the private-equity company that founded PediaMed. Previously, he practiced private law.

He is a graduate of Northern Kentucky University's Salmon P. Chase College of Law. A certified public accountant, Mr. Jennings also holds a B.A. in accounting from the University of Cincinnati.

Dr. Curtis **WRIGHT**

Javelin Appoints VP, Risk Management and Regulatory Affairs

Javelin Pharmaceuticals has named Curtis Wright, IV, M.D., as VP, risk management and regulatory affairs. Javelin is a New York-based specialty pharmaceutical company targeting unmet and underserved medical needs in the pain-management market.

Dr. Wright, a renowned authority on clinical risk assessment, most recently served as executive director for risk assessment and health policy at Purdue Pharma. He served at the U.S. Food and Drug Administration from 1989 to 1997 in the Center for Drug Evaluation and Research.

Dr. Wright graduated from Haverford College and completed his post-bachelor work at the Foundation for Advanced Education in the

Sciences at Trinity College. He earned his medical degree from George Washington University and master's of public health from the Johns Hopkins University.

Drug-Delivery **POOL**

James A. **VAUGHAN**

3M Names General Manager of Drug Delivery Systems Division



James A. Vaughan has been named general manager of 3M Drug Delivery Systems Division, St. Paul, Minn., which is a division of the 3M Health Care family of companies that develops inhalation and transdermal technologies.

Mr. Vaughan previously led 3M's European business for the Drug Delivery Systems and Pharmaceutical Divisions. He holds a B.S. with honors from Brighton School of Pharmacy Medicinal Chemistry, England.

Generic **POOL**

Michael **GRAVES**

John A. **MACPHEE**

Par Pharmaceutical Reorganizes Executive Staff

Par Pharmaceutical Companies has restructured its organization, creating two positions to manage its branded and generic pharmaceutical businesses. Located in Woodcliff Lake, N.J., Par develops, manufactures, and markets generic pharmaceuticals.

Michael Graves has been promoted to president of the generic products division, responsible for developing the strategy for Par's generic pharmaceutical business, as well as successfully executing its business plan. He has also been elected a corporate officer by the company's board of directors.

Mr. Graves, 43, has been with Par since 1998 and most recently served as senior VP, corporate development and strategic planning. He holds a B.S. from the State University College of New York at Buffalo.

Par also has promoted John A. MacPhee to

president of the branded products division, and the board of directors has elected him a corporate officer.

Mr. MacPhee previously served as senior VP, branded marketing and sales. Before joining Par in January 2005, Mr. MacPhee was VP of marketing for Forest Pharmaceuticals. He earned a MBA from New York University and a B.A. from Columbia College.

Agency POOL

Daniel **ANDERSON**

Jennifer **CERULLI**

Deanna **HOLLAND**

Tom **MAPLES**

Antoinette **PORTELLI**

Michael **SAHNS**

Tina **SIMITZ**

Todd **WILLIAMS**

Adient Makes Staff Changes

Adient, a CommonHealth professional advertising and promotion agency located in Wayne, N.J., has announced several changes to its staff.

Daniel Anderson has joined the agency as art director. He is responsible for the creation of new concepts and corresponding support materials for various brands. Most recently, he worked at Saatchi & Saatchi as a junior art director.

Jennifer Cerulli has been promoted to VP, account group supervisor. In this role, she is responsible for overseeing all tactical and strategic initiatives developed by her teams. She previously served as VP, account supervisor.



Deanna Holland has been promoted to VP, account supervisor, from account supervisor. In this role, she manages strategic and tactical initiatives while driving the growth of her assigned accounts.

Adient has hired Tom Maples as group copy supervisor. In this role, he leads concept and copy development within his group.

Previously, Mr. Maples was VP, associate creative director, at Adair-Greene.

Antoinette Portelli also has joined the

agency as senior designer. She works on layout design and photography retouching. Previously, Ms. Portelli was an art director for Lowe Bozell McAdams.

Michael Sahns has been promoted to assistant account executive. He is responsible for maintaining financial status reports and preparing medical and legal review submissions. He also runs client status meetings.



Tina Simitz has been promoted to VP, account group supervisor. She directs the strategic and tactical output of her designated accounts and manages individual members of her account team.

Todd Williams has rejoined Adient as a group art supervisor with responsibility for managing the day-to-day creative activity for his assigned brands. He spent two years with FCB HealthCare.

Donna **AREY**

Amie **CASSON**

Abelson-Taylor Adds Staff

Abelson-Taylor, an independent, Chicago-based healthcare advertising agency, has hired Donna Arey as senior copywriter. In this position, she assists in creative development and writing for several brands. Ms. Arey was a senior writer at Goble & Associates. She graduated magna cum laude with a B.A. in English literature from DePaul University and earned a master of science in journalism from Northwestern University.



Amie Casson also has joined Abelson-Taylor as senior account supervisor. She is responsible for supervising the brand initiative for Amgen's Neulasta, as well as managing all promotional activities.

Most recently, she was with Corbett Accel Healthcare as VP, senior account director. She holds a B.S. in microbiology from Miami University and a MBA from the Lake Forest Graduate School of Management. She is currently the first VP and 2006 president-elect of the Chicago Healthcare Businesswomen's Association Board of Directors.

Shelagh **BROOKE**

Dan **KATZ**

Steve **PASHKOFF**

Quantum Adds Staff

Quantum, Parsippany, N.J., the Common-

Health agency dedicated exclusively to building consumer healthcare brands, has hired Shelagh Brooke as executive VP, chief strategic officer. In this position, she is responsible for guiding strategic development for all Quantum brands. Most recently, she managed her own consulting firm, Strategic Stewardship.

Quantum also has hired Dan Katz as general manager, responsible for overseeing account functions, as well as client services. Previously, Mr. Katz spent nine years at Saatchi & Saatchi Consumer Healthcare, most recently as a managing director.

Steve Pashkoff has joined the firm as executive VP, chief creative officer. He works with senior management to lead and manage Quantum's creative teams. Previously, Mr. Pashkoff was employed at Saatchi & Saatchi Consumer Healthcare for eight years as an associate creative director.

Jonathan **COMMONS**

Stephen **LUBIAK**

Syed **MOINUDDIN**

Solara Promotes and Hires



Solara, CommonHealth's managed-care marketing unit based in Parsippany, N.J., has promoted Jonathan Commons to senior VP, management supervisor, responsible for directing the agency's strategic consulting and innovative tactical solutions in managed markets. He previously served as director of access strategy.



Solara also has hired Stephen Lubiak as senior VP, management supervisor, responsible for managing a key account team that provides a mix of managed-market consulting services and communications programs. Most recently, he worked for Intramed Educational Group, part of Sudler & Hennessey.



Syed Moinuddin also has joined Solara as director, access strategy. He is responsible for supporting the development and execution of Solara's tactical efforts with clients across multiple brands.

Mr. Moinuddin comes to Solara from the University of North Carolina's Kenan-Flagler Business School, where he graduated with a MBA while working for GlaxoSmithKline.

Carol **GRECO**
 Dr. Dennis **KLEINMAN**
 Nexus Adds Staff

Carol Greco has been named managing editor at Nexus Communications, an independent, global healthcare communications and education company based in North Wales, Pa. In this role, she is responsible for quality assurance on all Nexus products, and she provides editorial support to the firm's in-house medical writers. She brings 10 years of experience in the healthcare communications field.

Additionally, Dennis Kleinman, M.D., has joined Nexus as medical director. He has a clinical background in anesthesiology and pain management, as well as 20 years of experience in medical communications. His experience includes creating educational programs in such diverse therapeutic areas as central nervous system disorders, nephrology, osteoporosis, diabetes, and men's and women's health.

Graham **HALL**
 The Bravo Group Hires Chief Insights Officer



The Bravo Group, New York, a Hispanic marketing agency, has appointed Graham Hall to the newly created position of chief insights officer. He is responsible for overall development of the strategic and account planning functions throughout the agency, with special emphasis in the areas of cultural and youth insights.

Mr. Hall has more than 20 years of advertising experience on both the client and agency sides in the United States and United Kingdom. He previously operated the youth brand development agency Informer.

Chet **MOSS**
 Integrated Communications Appoints Creative Leader



Integrated Communications has appointed Chet Moss to the newly created position of executive VP, chief creative officer. Integrated Communications, a division of Lowe Healthcare Worldwide, is a medical advertising agency based in Parsippany, N.J. In this new role, Mr. Moss oversees the company's entire creative process.

Most recently, he was with Euro RSCG Life, where he served as executive VP, creative director, for the company's flagship agency, LM&P.

Dr. Elizabeth **PACZOLT**
 Dr. Catherine **PIONTEK**
 Dr. Amy **SUPNICK**
 Interlink Hires Medical Directors

Interlink Healthcare Communications, Lawrenceville, N.J., has hired Elizabeth Paczolt, M.D., Catherine Piontek, M.D., and Amy Supnick, M.D., as medical directors. Interlink is a full-service healthcare advertising and medical education company.



Dr. Paczolt has joined the agency's medical strategy and communications department. She most recently served in dual roles at Deborah Heart and Lung Center as codirector of the section of nuclear medicine and as radiation safety officer. She also chairs the Medical Society of New Jersey's committee on medical education.

Dr. Piontek is a board-certified psychiatrist. She previously held appointments in the departments of psychiatry at several universities; most recently, she was assistant professor of psychiatry and human behavior at Thomas Jefferson University.

She earned her M.D. from the State University of New York, Buffalo, completed her ob/gyn residency at Temple University Hospital and Thomas Jefferson University Hospital, and her psychiatry residency at Medical College of Pennsylvania.



Dr. Supnick also has joined Interlink's medical strategy and communications department. An endocrinologist and internist, she adds a unique combination of clinical experience and business acumen to the

Interlink team.

Previously, she maintained a private practice in clinical endocrinology and performed research in the field, concentrating on osteoblast growth. She completed the MBA program at La Salle University.

Diane **PERRY**
 Noonan Russo Expands Senior Management Team

Noonan Russo has appointed Diane Perry



as senior VP and managing director of the firm's corporate communications group. She is responsible for managing clients' public and investor relations programs and for leading ongoing new business efforts. Noonan Russo, New York, is a global health consultancy and a division of Euro RSCG Life PR.

Ms. Perry has more than 20 years of experience as a corporate communications and investor relations practitioner. Most recently, she was an equity partner at Kodora Communications. She received her B.S. in biology with honors from Stockton College.

Laura **PERRY**
 Altum Appoints VP

Altum, Parsippany, N.J., CommonHealth's full-service professional healthcare advertising and promotion company, has hired Laura Perry as VP, account group supervisor. She is responsible for developing strong and enduring business relationships with assigned client brands and teams.

Previously, Ms. Perry served as VP, senior director, at Corbett Accel Healthcare, where she led strategic positioning and branding development.

Dr. Steven **PESKIN**
 MediMedia Hires Chief Medical Officer



MediMedia USA, a healthcare communications firm based in Chatham, N.J., has appointed Steven Peskin, M.D., as executive VP and chief medical officer. Previously, Dr. Peskin was CEO of Pharmaceutical Research Plus.

A fellow of the American College of Physicians, Dr. Peskin earned his M.D. from Emory University School of Medicine and completed his internal medicine residency at St. Elizabeth's Medical Center in Boston.

He earned his MBA, with a concentration in healthcare, at the Sloan School of Management at the Massachusetts Institute of Technology.

John **QUICK**
 HealthSTAR PR Hires Client Services Director

John Quick has joined the executive man-



agement team at HealthSTAR Public Relations as director of client services. HealthSTAR PR, New York, a division of HealthSTAR Communications, is a full-service agency dedicated solely to healthcare, medical, and pharmaceutical communications to professional and consumer audiences.

Mr. Quick most recently served on AstraZeneca's marketing team, supporting Seroquel for schizophrenia and bipolar mania. He received a B.A. in communications/English from the State University of New York at Plattsburgh and a M.S. in communications from Iona College.

CRO POOL

Dr. David **BROWN**

David **PROVOST**

PPD Adds Senior Leadership



PPD, a global CRO based in Wilmington, N.C., has appointed David Brown, Ph.D., as senior director of pharmacovigilance and epidemiology. He directs the company's postmarket pharmacovigilance offerings, including registries and risk management tools.

Before joining the company, Dr. Brown held several senior-level positions in epidemiology and global safety surveillance at Wyeth Research, including epidemiology team leader for oncology and neurosciences.

He holds a doctorate in epidemiology from the University of Alabama at Birmingham, a MPH from Loma Linda University, and a master's degree in cellular and molecular biology from the University of California at Riverside.



Additionally, PPD has hired David Provost to the newly created position of executive director of market development strategic operations. He provides strategic design and implementation oversight for late-stage

trials, patient registries and observational studies, postapproval safety surveillance studies, and risk management programs.

Mr. Provost has been with PPD since 1995, when he joined the CRO as a director. He most recently served as executive director for registries and observational studies, compliance, and risk management programs.

Pierre **DEVESLY**

Anthony L. **FORCELLINI**

Kendle Makes Appointments



Kendle, a global, full-service clinical research organization based in Cincinnati, has appointed Pierre Devesly as clinical project group leader, responsible for direction of Phase I to Phase III clinical development projects for the company's biopharmaceutical customers. He is assigned to Kendle's Americas operating unit and is based out of the Cranford, N.J., office.

Mr. Devesly has more than 18 years of clinical development expertise spanning multiple therapeutic areas. Most recently, he was group director, project management, at Quintiles Transnational. He earned a B.S. in biology from the State University of New York at Binghamton.

Also, Kendle has promoted Anthony L. Forcellini to VP of strategic development and corporate treasurer. In this newly created position, he leads the CRO's strategic business expansion and diversification efforts, focusing on new service areas.

Mr. Forcellini originally joined Kendle in 1996 and most recently served as VP of technical operations. Before that, he spent seven years at Hook-SupeRx. He is a certified public accountant and holds a B.S. in accounting and finance from Miami University.

Mr. Forcellini originally joined Kendle in 1996 and most recently served as VP of technical operations. Before that, he spent seven years at Hook-SupeRx. He is a certified public accountant and holds a B.S. in accounting and finance from Miami University.

Media POOL

Ken **FREIRICH**

Health monitor Appoints Senior VP

Health monitor Network, a New York-based multimedia consumer-health/patient-education publishing company, has hired Ken Freirich as senior VP.

Mr. Freirich has 15 years of senior-level

experience in the pharmaceutical industry, most recently as CEO of TransLocal Health. A graduate of Skidmore College, he completed the executive MBA certificate program at Columbia University Graduate School of Business, through the Thomson Information Publishing Management Development program.

Medical-Education POOL


Linda **CALDWELL**

Diane **PARKER**

Curry Rockefeller Hires and Promotes

The CRG Oncology division of The Curry Rockefeller Group has named Linda Caldwell as director of oncology. Curry Rockefeller, Tarrytown, N.Y., provides thought-leader-focused medical education. In this role, Ms. Caldwell assists in clinical project oversight and new business development.

Ms. Caldwell's career includes more than 10 years with Schering-Plough, where she most recently served as director of clinical consultants. She earned a M.S. in nursing from Rutgers University and a B.S. from the University of San Francisco in California.



Curry Rockefeller also has promoted Diane Parker to VP of business services. Her responsibilities include general management, budgets and financial planning, human resources, information systems, IT, facilities, capital asset procurement, and supply control.

Before joining Curry Rockefeller in 2001, Ms. Parker served as senior VP, regional manager, of First Fidelity Bank. She holds a MBA in economics and finance from St. John's University and a B.A. in English and education from Mount Saint Mary College.

Dipika **DABHI**

Conor **FOGARTY**

HLS Adds Staff

HLS (Health Learning Systems), CommonHealth's founding medical-education unit, located in Wayne, N.J., has hired Dipika Dabhi as program coordinator in the program-management division. She is responsible for ensuring timely program development, trafficking the various stages of program ele-

ments, and working with faculty and sponsors for necessary approvals.


Previously, she worked in the quality-assurance department at Dendrite International. She is working toward her B.S. in finance at Rutgers University.

Also, Conor Fogarty has come to HLS as program coordinator for the publication sector. He is responsible for developing timelines and trafficking materials to ensure a steady work flow for his assigned teams.

Mr. Fogarty previously was an intern with The Franklin Groups. He holds a B.A. in economics and political science from Columbia University.

Kim VADAS

Scienta Appoints Program Manager



Kim Vadas has joined the staff of Scienta Healthcare Education as program manager in the therapeutic areas of migraine and hemophilia. Scienta, Durham, N.C., is dedicated to the development and dissemination of continuing medical education. Ms. Vadas plays a leading role in planning and implementing new continuing medical education initiatives.

She previously worked with CommGeniX as a project manager on continuing medical education activities in the therapeutic area of sleep disorders. She currently is completing her study toward a master's degree in medical ethics at the University of South Florida.

Service POOL

Michael J. CAVANAUGH

Laureate Hires Sales Executive

Michael J. Cavanaugh has been named VP of sales, marketing, and business development at Laureate Pharma, Princeton, N.J., a contract manufacturing and services company serving pharmaceutical and biopharmaceutical companies.

Previously, Mr. Cavanaugh served as VP of marketing and sales support for North America with Amersham/GE Healthcare. He holds a B.S. in biology, with a minor in chemistry, from Fairfield University and a master's in clinical microbiology, with a minor in biochemistry, from Hahnemann Medical College.

Michael FRONSTIN

Consumer Health Sciences Hires VP



life-sciences companies.

Mr. Fronstin brings to CHS more than a decade of experience in pharmaceutical and healthcare marketing research and consulting. Most recently, he was director of strategic consulting services at TargetRx.

Richard HOOTEN

Brad PATTEN

Jeffrey L. THOMAS

Ventiv Hires and Promotes



Mr. Hooten has more than 22 years experience, most recently as executive director of operations for Ranbaxy Laboratories. He holds a B.B.A. from the University of Central Arkansas.

Ventiv Access Services has promoted Brad Patten to VP of business development.



recently was president of Ranbaxy Laboratories.

Ken KATZ

Susan MONTANILE

Rich O'DONNELL

Scientific Publishing Builds Sales Team

Scientific Publishing, a medical chart and

anatomical model company based in Rolling Meadows, Ill., has appointed Ken Katz as VP of sales. He previously served as director of sales at Medi-Promotions.

The company has also hired Susan Montanile as sales consultant in the east. She formerly was VP of marketing at Medi-Promotions.

Rich O'Donnell has joined Scientific Publishing as a sales consultant in the midwest/west. He was most recently with Health Media Group.

Dr. David ONIONS

Invitrogen Promotes Chief Medical Officer

Invitrogen, Carlsbad, Calif., a provider of essential life-sciences technologies for disease research, drug discovery, and commercial bioproduction, has promoted David Onions, Ph.D., to the newly created position of chief medical officer.

He is responsible for guiding the company's scientific efforts as Invitrogen moves into areas more closely associated with medical research and patients, such as stem-cell technologies, diagnostics support, and other clinical studies.

Dr. Onions, who originally joined Invitrogen in 2003, previously was a founder and director of Q-One Biotech.

He holds a B.V.Sc. from Bristol University and a Ph.D. from the University of Cambridge.

Seth RUTLEDGE

MTI Names VP, Product Management

MTI Information Technologies has appointed Seth Rutledge as VP of product management, responsible for the ongoing development and support of the company's flagship product, the eXtendRx sales optimization program.

MTI, Langhorne, Pa., provides data-driven, technology-based, direct-to-physician marketing programs.

Most recently, Mr. Rutledge was at FairIsaac, where he was responsible for clients' implementation of best practices database marketing projects involving both technology and processes.

He earned a B.S. from the University of North Carolina at Charlotte. ♦

Please send your personnel announcements to feedback@pharmavoices.com.